sorafenib has been researched along with Hemorrhage in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, W; Ghim, JL; Liu, S; Parvez, M; Shin, JG; Sun, H; Tang, Z; Wang, Z; Xiang, X | 1 |
| Dai, C; Shao, JH; Wu, LQ; Yin, XB; Yu, X; Zhou, F | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S | 1 |
| Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D | 1 |
| Maitland, ML; Snider, KL | 1 |
| Chen, HX; Cleck, JN | 1 |
| Choueiri, TK; Je, Y; Schutz, FA | 1 |
| Montalvo, RO; Moretti, LV | 1 |
| Minor, DR | 1 |
| Flaig, MJ; Prinz, JC; Rübsam, K; Ruzicka, T | 1 |
| Caravetta, A; Guarino, R; Mollo, F; Peluso, L; Rombolà, F; Spinoso, A | 1 |
| Artéaga, C; Brardjanian, S; Coton, T; Fabries, P; Guisset, M; Pauleau, G | 1 |
| Duffy, A; Greten, TF; Wilkerson, J | 1 |
| Armand, JP; Escudier, B; Faivre, S; Raymond, E; Robert, C | 1 |
| Kamba, T; McDonald, DM | 1 |
8 review(s) available for sorafenib and Hemorrhage
| Article | Year |
|---|---|
Bleeding risk in cancer patients treated with sorafenib: A meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Hemorrhage; Humans; Incidence; Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib; Treatment Outcome | 2018 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.
Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hemorrhage; Humans; Hypertension; Indoles; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Niacinamide; Pain; Pancytopenia; Phenylurea Compounds; Protease Inhibitors; Pyrroles; Salvage Therapy; Sepsis; Sorafenib; Sunitinib | 2015 |
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Routes; Female; Hemorrhage; Humans; Hypertension; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Adverse effects of anticancer agents that target the VEGF pathway.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Brain Diseases; Capillary Leak Syndrome; Cardiovascular Diseases; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Forecasting; Gastrointestinal Diseases; Hemorrhage; Humans; Indoles; Kidney Diseases; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing | 2009 |
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Hemorrhage; Humans; Incidence; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sorafenib; Sunitinib | 2009 |
Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Hemorrhage; Humans; Incidence; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib | 2013 |
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Thrombosis; Vascular Endothelial Growth Factor A; Wound Healing | 2007 |
8 other study(ies) available for sorafenib and Hemorrhage
| Article | Year |
|---|---|
A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib.
Topics: Anticoagulants; Blood Coagulation; Computer Simulation; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Drug Interactions; Hemorrhage; Humans; International Normalized Ratio; Models, Biological; Models, Theoretical; Pharmacogenomic Testing; Risk Assessment; Sorafenib; Vitamin K Epoxide Reductases; Warfarin | 2021 |
Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Comorbidity; Drug Interactions; Drug Monitoring; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Platelet Aggregation Inhibitors; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Tumor Burden; Venous Thrombosis | 2015 |
Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin.
Topics: Aged; Anticoagulants; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Interactions; Hemorrhage; Humans; International Normalized Ratio; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Warfarin | 2009 |
Risk of bleeding not increased by sorafenib or sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2010 |
Erythema marginatum hemorrhagicum: a unique cutaneous side effect of sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Erythema; Hemorrhage; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Terminology as Topic | 2011 |
Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hemorrhage; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Rupture, Spontaneous; Sorafenib | 2011 |
[Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenal Glands; Antineoplastic Agents; Carcinoma, Hepatocellular; Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Nail Diseases; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2005 |